Andrew Kocab

.@ONLTherapeutics is pioneering a new way to treat retinal diseases by preventing retinal cell death. #JNJInnovation is proud to support their journey to bring this potential breakthrough therapy to patients. Learn more: jji.jnj/ONL #JNJSpecialtyOphthalmology

Our work with our great academic collaborators just published! Thanks to all of our contributors for their great work! tvst.arvojournals.org/article.aspx?a…

Congratulations to the @ONLTherapeutics team on a successful Ser. C that will power the RD Phase 2 trial and extend runway to prepare for 2 more Ph 2 studies in chronic conditions. @D_A_Esposito @cchangmba @CuriousKocab exsightventures.com/blog/onlsersc1

Congrats to the team! Big news!

Congrats to the team!

Just finished a great OIS XII 2022 Meeting. So grateful for the OIS team for putting on a great event. Also thankful for the hard work of the ONL team and the VCs and investment bankers in attendance that awarded @ONLTherapeutics the 2022 Ophthalmology Innovation Award! Thank you

It has been a few great days in Melbourne AUS visiting our study sites and witnessing first-hand the hard work of our partners in the clinics. I want to thank Professor Robyn Guymer (CERA) for a great talk on Geography Atrophy to many clinicians in the city. @ONLTherapeutics

Just finishing up time with our clinical teams in Melbourne AUS. I am grateful for the courage & sacrifice patients are making when they participate in our trials. To say “yes” to a First-in-Human Phase 1 study is a courageous decision. Thank you to our patients.@ONLTherapeutics

Congrats to @CraigFreshley on his new book. Looking forward to reading it and learning how to make better group decisions! amazon.com/Together-We-De…

Great addition! Looking forward to working with you, Lindsay! Welcome to the team!

@ONLTherapeutics Looking forward to working with Sushanta! Welcome to the team!

The team is growing! We're thrilled to announce that Sushanta Mallick is our new Chief Development Officer. We're excited that he's joined us on our mission to protect the vision of patients with retinal diseases! onltherapeutics.com/2022/02/09/onl…

Our review article was just published in the Journal of Clinical Medicine! We describe the role of Fas signaling in AMD progression (and sneak in some original data). Big thanks to my co-authors for their valuable contributions to this work! mdpi.com/2077-0383/11/3…

We just closed on our second tranche of our Series B financing! Great effort by the team, and we look forward to continuing to advance our development efforts to protect the vision of patients with retinal disease. onltherapeutics.com/2022/01/13/onl…

New blog post on how @USDA scientist @LabSummers is researching how to keep our pork supply healthy and efficient. The key? Pig poop. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog! curiouskocab.com/blog/saving-ou…

New blog post highlighting the vaccine technology being developed by Iaso Therapeutics. Cool platform that uses bacteriophage to make better vaccines. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog! curiouskocab.com/blog/building-…

New blog post highlighting Zack Abbott's path to create @ZBioticsCompany and the company's genetically engineered probiotic. Thanks to @QIAtodd_MI and @QIAGEN for sponsoring the blog! curiouskocab.com/blog/creating-…

Welcome to ONL, Amanda! Looking forward to working with you

My blog's Esposito Trilogy on biotech fundraising & @ONLTherapeutics is complete! Thanks to David Esposito for all of the lessons. Thanks @QIAGEN and @QIAtodd_MI for sponsoring the blog! curiouskocab.com/blog/raising-m…

Another blog post on David Esposito's approach to fundraising, describing how @ONLTherapeutics told its story to investors and refined it along the way. Thanks to @QIAGEN and @QIAtodd_MI for sponsoring the blog! curiouskocab.com/blog/raising-m…